SOLSSolstice Advanced Materials, Inc.

$61.39

Is the business good?

Mixed

The checks split: nothing decisive, though 3 of 9 health tests passed.

1 to watch, 1 neutral, 2 without data
Fundamental health (F-score)3 / 9SEC EDGAR · Dec 31, 2025

Weak, deteriorating fundamentals. Nine pass/fail tests of year-over-year health from the filings.

Where ROE comes from4% ROAderived

A balanced mix of margins, efficiency, and leverage. ROE 13% = margin × turnover × leverage.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionmiddle of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is SOLS?

Solstice Advanced Materials, Inc. keeps 5.1% of every revenue dollar as profit after everything, against 4.8% for the median Specialty Chemicals name.

5.1%

Net margin · Specialty Chemicals median 4.8% · 12 months to Q2 2026

Share count, year on year
+0.44%

Share count, year on year · flat: no meaningful dilution

R&D as % of revenue
2.6%

R&D as % of revenue

Gross margin
31%

Gross margin

Details›
Gross margin12 months to Q2 2026
31%
Net margin12 months to Q2 2026
5.1%
Free cash flow margin
4.8%
R&D as % of revenue
2.6%
Revenue, trailing twelve months
$4.09B
Free cash flow, trailing twelve months
$195M
Net income, trailing twelve months
$210M

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.